CyPath® Lung Connect Forums

CyPath® Lung by bioAffinity Technologies
  • 0,0 (0)
  • Médecine

CyPath® Lung Connect brings together leading voices in pulmonology, oncology, and lung health to explore the evolving landscape of early lung cancer detection. Through clinical insights, real-world case studies, and expert conversations, the series covers topics such as lung cancer screening, risk stratification, early diagnosis, clinical decision-making and emerging technologies. From screening through survivorship, the series highlights perspectives shaping the future of lung health, including the role of noninvasive diagnostic technologies like CyPath® Lung.

Épisodes

  1. -5 j

    From CT to Sputum: Rethinking Lung Nodule Risk in Veterans

    Veterans face disproportionately high rates of lung cancer, often diagnosed too late for the most effective treatments. In this episode, NAVREF CEO Rashi Romanoff and RWJBarnabas Health pulmonologist Dr. Michael Nicholson explore how CyPath Lung, a non-invasive, home-based sputum test powered by AI, can transform lung cancer screening and early detection for veterans.

  2. 12 août

    Real-World Lung Nodule Cases: Risk Stratification, Multidisciplinary Collaboration and the Role of CyPath® Lung

    In this episode, a multidisciplinary panel of pulmonology, thoracic surgery and oncology experts discusses real-world lung nodule cases and how noninvasive CyPath® Lung testing can help refine risk stratification. The panel explores when testing may support decisions to pursue biopsy, when a negative result may help avoid unnecessary invasive procedures, and how multidisciplinary collaboration can improve the management of patients with indeterminate lung nodules. The experts also look ahead to the evolving role of noninvasive testing in lung nodule management.

  3. 4 août

    Navigating Lung Nodules in High-Risk Patients: The Role of CyPath® Lung

    In this episode, a multidisciplinary panel - an interventional pulmonologist, thoracic surgeon, and medical oncologist - explores the growing challenge of indeterminate lung nodules in high-risk patients. The experts discuss the limitations of current risk-stratification approaches and how CyPath® Lung, a noninvasive sputum-based test, can provide objective information to help clinicians better assess the likelihood of malignancy and guide decisions about follow-up, surveillance, or biopsy.

  4. 10 juin

    CyPath® Lung in Clinical Practice: Pulmonologists Roundtable

    In this episode, the pulmonologists participating in a roundtable discussion go beyond the challenges of pulmonary nodule management to discuss how CyPath® Lung is being integrated into real-world clinical workflows. The panel explores patient anxiety and stigma, when to biopsy and when not to, and how a noninvasive sputum-based test can risk stratify and help guide next steps for patients with indeterminate pulmonary nodules. The discussion also takes a deeper look at the science behind CyPath® Lung and offers compelling patient cases—including a smoker ultimately diagnosed with Stage I lung cancer and a heart transplant candidate with a difficult-to-access pulmonary nodule.

  5. 2 juin

    Enhancing Clinical Confidence: Managing Small Pulmonary Nodules with CyPath® Lung

    A panel of pulmonologists discuss their use of CyPath® Lung in clinical practice as part of a comprehensive approach to lung cancer risk assessment, pulmonary nodule management, and surveillance of lung cancer survivors post-treatment. A key theme that emerges from the conversation is how CyPath® Lung enhances clinical confidence in determining appropriate next steps for patients at risk for lung cancer. Moderator: Gordon Downie, MD, PhD bioAffinity Technologies Chief Medical Officer Panelists: ·      Sai Karan Vamsi Guda, DO Interventional pulmonologist with Texas Pulmonary & Critical Care Consultants ·      Michael Nicholson, DO Pulmonologist and critical care specialist with RWJBarnabas Health Medical Group  ·      Gregory White, MD Pulmonologist at CHRISTUS Trinity Clinic

    Enhancing Clinical Confidence: Managing Small Pulmonary Nodules with CyPath® Lung
  • 5 épisodes

À propos

CyPath® Lung Connect brings together leading voices in pulmonology, oncology, and lung health to explore the evolving landscape of early lung cancer detection. Through clinical insights, real-world case studies, and expert conversations, the series covers topics such as lung cancer screening, risk stratification, early diagnosis, clinical decision-making and emerging technologies. From screening through survivorship, the series highlights perspectives shaping the future of lung health, including the role of noninvasive diagnostic technologies like CyPath® Lung.

Informations

  • Création
    CyPath® Lung by bioAffinity Technologies
  • Années d’activité
    2026
  • Épisodes
    5
  • Classification
    Tous publics
  • Copyright
    © CyPath® Lung by bioAffinity Technologies
  • Site web de l’émission
    CyPath® Lung Connect Forums